Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

Summary

This will be a randomized, open-label, controlled trial of patients at high risk of developing preeclampsia examining 81 mg/day vs 162mg/day daily acetylsalicylic acid (ASA) use. Based on screening results, patients will be randomized as outlined below into one of four groups. The proposed study is a pilot to determine if the higher dose of ASA has positive impacts on measures that predict preeclampsia, compared to the lower dose. If positive findings, data from this study could be used to develop a larger trial powered to determine if the higher ASA dose can improve clinical outcomes.

Timeline

Start

2022-10-01

Primary completion

2023-12-31

Completion

2025-12-31

Drugs

Indications